Diabetic Kidney Disease
General DKD Information
10 links
- Diabetic Kidney Disease: Challenges, Progress, and Possibilities
- The Global Epidemiology of Diabetes and Kidney Disease
- Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease
- Preserving Kidney Function Instead of Replacing It
- Implications of Specialist Density for Diabetes Care in the United States
- Cardio-Renal-Metabolic Care Models Toward Achieving Effective Interdisciplinary Care
- Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
- Health Care Access and Use Among Adults with Diabetes During the COVID-19 Pandemic — United States, February–March 2021
- Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria
Complications of DKD
4 links
- Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
- Global trends in diabetes complications: A review of current evidence
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database
Outcomes and Data Associated with DKD
9 links
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
- Centers for Disease Control and Prevention: National Diabetes Statistics Report
- International Diabetes Federation: IDF Diabetes Atlas, 9th Ed
- Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
- Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
- Heart Disease and Stroke Statistics—2021 Update
- Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children An Analysis of the CURE-CKD Registry
- Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials.
Medications Associated with DKD
16 links
- Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States
- Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
- Dapagliflozin in Patients with Chronic Kidney Disease
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial
- Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
- Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease
- Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
- Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence
- Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: Findings based on the EMPA-REG OUTCOME Trial
- The Medical Letter: Comparison Chart: Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
- In the Years Before the COVID-19 Pandemic, Nearly 13 Million Adults Delayed or Did Not Get Needed Prescription Drugs Because of Costs
- Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
DKD and the Pediatric Population
2 links
DKD Payment and Drug Pricing
3 links
DKD and Diversity/Equality
6 links
- Reported Racial Discrimination, Trust in Physicians, and Medication Adherence Among Inner-City African Americans With Hypertension
- Beyond Consent: Building Trusting Relationships with Diverse Populations in Precision Medicine Research
- Effects of Community-Based Health Worker Interventions to Improve Chronic Disease Management and Care Among Vulnerable Populations: A Systematic Review
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
- Time to Eliminate Health Care Disparities in the Estimation of Kidney Function
Diabetic Kidney Disease (DKD-C) Strategy Conference Series
Implementing New Diabetic Kidney Disease Treatments – Time to Act (June 16, 2021)
4 links
Implementing New Diabetic Kidney Disease Treatments – Time to Act (April 20, 2021)
3 links
Implementing New Diabetic Kidney Disease Treatments – Time for Nephrologists to Act (January 14, 2020)
2 links
Diabetic Kidney Disease (DKD-C) Videoconference Series
Management of Diabetes & Kidney Disease through COVID-19
4 links
Goal-Directed Medical Therapies (GDMT) for Patients with Diabetic Kidney Disease and Beyond
3 links
